Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.

Abraham AA, Lang H, Meier ER, Nickel RS, Dean M, Lawal N, Speller-Brown B, Wang Y, Kean L, Bollard CM.

Pediatr Blood Cancer. 2019 Jan 4:e27601. doi: 10.1002/pbc.27601. [Epub ahead of print]

PMID:
30609269
2.

Assessing Disease Knowledge and Self-Management in Youth With Sickle Cell Disease Prior to Transition.

Speller-Brown B, Varty M, Thaniel L, Jacobs MB.

J Pediatr Oncol Nurs. 2018 Dec 19:1043454218819447. doi: 10.1177/1043454218819447. [Epub ahead of print]

PMID:
30565490
3.

Comprehensive Infant Clinic for Sickle Cell Disease: Outcomes and Parental Perspective.

Martin BM, Thaniel LN, Speller-Brown BJ, Darbari DS.

J Pediatr Health Care. 2018 Sep - Oct;32(5):485-489. doi: 10.1016/j.pedhc.2018.04.018. Epub 2018 Jul 4.

PMID:
30180940
4.

Views of parents of children with sickle cell disease on pre-implantation genetic diagnosis.

Darbari I, O'Brien JE, Hardy SJ, Speller-Brown B, Thaniel L, Martin B, Darbari DS, Nickel RS.

Pediatr Blood Cancer. 2018 Aug;65(8):e27102. doi: 10.1002/pbc.27102. Epub 2018 Apr 18.

PMID:
29667775
5.

Inhaled corticosteroid use to prevent severe vaso-occlusive episode recurrence in children between 1 and 4 years of age with sickle cell disease: a multicenter feasibility trial.

Vance Utset L, Ivy Z, Willen SM, Rodeghier M, Watt A, Schilling L, Jenkins CL, Pepper S, Speller-Brown B, Darbari DS, Majumdar S, Adisa O, DeBaun MR.

Am J Hematol. 2018 Aug;93(4):E101-E103. doi: 10.1002/ajh.25033. Epub 2018 Feb 5. No abstract available.

PMID:
29322539
6.

International and Interdisciplinary Identification of Health Care Transition Outcomes.

Fair C, Cuttance J, Sharma N, Maslow G, Wiener L, Betz C, Porter J, McLaughlin S, Gilleland-Marchak J, Renwick A, Naranjo D, Jan S, Javalkar K, Ferris M; International and Interdisciplinary Health Care Transition Research Consortium.

JAMA Pediatr. 2016 Mar;170(3):205-11. doi: 10.1001/jamapediatrics.2015.3168.

PMID:
26619178
7.

Measuring Transition Readiness: A Correlational Study of Perceptions of Parent and Adolescents and Young Adults with Sickle Cell Disease.

Speller-Brown B, Patterson Kelly K, VanGraafeiland B, Feetham S, Sill A, Darbari D, Meier ER.

J Pediatr Nurs. 2015 Sep-Oct;30(5):788-96. doi: 10.1016/j.pedn.2015.06.008. Epub 2015 Jul 18.

PMID:
26195300
8.

Unruptured intracranial aneurysms in children with sickle cell disease: analysis of 18 aneurysms in 5 patients.

Saini S, Speller-Brown B, Wyse E, Meier ER, Carpenter J, Fasano RM, Pearl MS.

Neurosurgery. 2015 May;76(5):531-8; discission 538-9; quiz 539. doi: 10.1227/NEU.0000000000000670.

PMID:
25710108
9.

Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial.

Kalpatthi R, Thompson B, Lu M, Wang WC, Patel N, Kutlar A, Howard T, Luchtman-Jones L, Miller ST; BABY HUG Investigators.

Clin Biochem. 2013 Feb;46(3):278-81. doi: 10.1016/j.clinbiochem.2012.10.032. Epub 2012 Oct 31.

10.

Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.

Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, Thompson B, Howard T, Iyer RV, Rana SR, Rogers ZR, Sarnaik SA, Thornburg CD, Ware RE; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Oct;59(4):668-74. doi: 10.1002/pbc.24100. Epub 2012 Jan 31.

11.

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators.

Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.

12.

Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial.

Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE; BABY HUG.

Blood. 2011 Mar 3;117(9):2614-7. doi: 10.1182/blood-2010-04-278747. Epub 2011 Jan 7.

13.

Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, Shulkin BL, Shalaby-Rana E, Strife CF, Miller JH, Lane PA, Wang WC, Miller ST; BABY HUG Investigators.

J Pediatr. 2010 Jan;156(1):66-70.e1. doi: 10.1016/j.jpeds.2009.06.060.

14.

Reversible posterior leuko-encephalopathy in children with sickle cell disease.

Khademian Z, Speller-Brown B, Nouraie SM, Minniti CP.

Pediatr Blood Cancer. 2009 Mar;52(3):373-5. doi: 10.1002/pbc.21812.

PMID:
19003906
15.

Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.

Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP.

Pediatr Blood Cancer. 2006 Dec;47(7):894-900.

PMID:
16526051

Supplemental Content

Loading ...
Support Center